Effect of the Antioxidant Micronutrients of Rapeseed Oil on the Prevention of Cardiovascular Diseases (Optim'Oils)

NCT ID: NCT00852735

Last Updated: 2010-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases.

Randomised crossover dietary intervention study:

The main objective of the clinical study is to investigate the effect of the consumption of an "optimized" rapeseed oil on the lipid metabolism of volunteers as compared with the consumption of a "reference" oil.

Post prandial study:

The second objective of the clinical study is to investigate the effect of the consumption of an "optimized" rapeseed oil on the biomarkers of oxidative stress during post prandial period as compared with the consumption of a "reference" oil.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For both studies, sedentary men between 30 and 65 years of age, with a BMI between 25 and 30, without cardiovascular disorders, will be selected.

Randomised crossover dietary intervention study:

Sixty volunteers will be randomised into 2 groups of 30. The study will last 12weeks. The first 3 weeks will be an adaptation period or "run in". Volunteers will have every day20 g of the reference rapeseed oil and 20 g of the reference oil-based rapeseed margarine. Subsequently, the two groups will follow 2 dietary intervention periods of 3 weeks during which the volunteers will have alternatively either the reference oil/margarine or the optimized oil/margarine. Three weeks of "wash out" will separate the two dietary interventions of the cross over design trial.

Cardiovascular risk and oxidative stress biomarkers will be assessed in plasma at week 0, 3, 6, 9 and 12.

Volunteers will alsoperform dietary surveys at the week 3, 6, 9 and 12.

Post prandial study:

16 volunteers will be cast lots among the 60 volunteers. They will be randomised into 2 groups of 8. The first kinetic study will be done on week 3. 8 subjects will take 66 g of reference oil and 8 subjects will take 66 g of the optimized oil. 5 blood samples (20 mL each) will be taken.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rapeseed Oil (prevention of cardiovascular diseases)

to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* Age : 30 to 65
* Body mass index between 25 and 30 kg/m²
* Weight lower than 110 kg
* Subject considered as normal after clinical examination and medical questionnaire
* Subject giving his written informed consent
* Subject willing to comply with the study procedures
* Affiliated to National Health Insurance

Exclusion Criteria

* Biological results judged abnormal by investigator
* Positive serologies to HIV or HCV
* Previous medical and/or surgery judged by the investigator as incompatible with the study
* Taking medicine: hypocholesterolemic,beta blockers, IEC,
* Diabetes1 and 2
* High blood pressure
* Digestive, cardiovascular, renal, liver, tumor or thyroid diseases in the last 5 years
* Infectious or inflammatory diseases in the last 5 years
* Previous heavy intestine surgery (except appendectomy)
* Triglycerides\> 4 g/L
* Dyslipidemia: HDL cholesterol\< 0.4 g/L or LDL/HDL\>6.25
* blood donation done less than 2 month before the start of the study
* Particular diet: vegetarian, vegan...
* Anormal dietary habits
* Consumption of food complements: antioxidant, ...
* intense physical exercise practise (\>5 h per week)
* Tobacco, alcohol:more than 30 g of alcohol/day, i.e.3 glasses/day, smoking \> 5 cigarettes /day
* No affiliated to National Health Insurance people
* Refusal to sign informed consent
* Refusal to be registered on the National Volunteers Data file
* Currently participating or who having got 4500 E in this year before to have participated in another clinical trial
Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre de Recherche en Nutrition Humaine d'Auvergne

OTHER_GOV

Sponsor Role collaborator

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

OTHER

Sponsor Role collaborator

ITERG

INDUSTRY

Sponsor Role collaborator

Unilever R&D

INDUSTRY

Sponsor Role collaborator

Lesieur

INDUSTRY

Sponsor Role collaborator

University Hospital, Clermont-Ferrand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

CRNH Auvergne

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Noël Cano

Role: PRINCIPAL_INVESTIGATOR

Centre de Recherche en Nutrition Humaine d'Auvergne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CRNH Auvergne

Clermont-Ferrand, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AU 759

Identifier Type: -

Identifier Source: secondary_id

CHU-0047

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.